⏳ Fetching live dividend data...
Home › Calculator › TAIPY Dividend Calculator 2026
Taisho Pharmaceutical Holdings Co., Ltd. · OTC
Price: $14.00 · Annual div: $0.17/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in TAIPY → $17.0K in 10 years · $4.31/month
Taisho Pharmaceutical Holdings Co., Ltd. is a global healthcare entity engaged in the comprehensive process of researching, developing, manufacturing, marketing, distributing, and selling both over-the-counter (OTC) and prescription pharmaceutical products. The company operates across Japan and internationally, structuring its diverse activities into two principal divisions: the Self-Medication Operation Group and the Prescription Pharmaceutical Operation Group. The Self-Medication Operation Group concentrates on consumer health, offering an extensive selection of non-prescription drugs, quasi-pharmaceuticals, nutritional products, and general medical and hygiene supplies. Its prominent brands encompass the popular Lipovitan range of energy drinks; the Pabron series for cold and sinus relief; RiUP products designed for hair re-growth; Taisho Kampo, specializing in gastrointestinal treatments; Colac laxatives; Naron and other antipyretic analgesics; Preser for hemorrhoid care; and a variety of international antipyretic analgesics such as Hapacol, Efferalgan, Dafalgan, and Tempra. This segment also provides Counterpain topical anti-inflammatory pain relievers, Vitacilina for dermatological conditions, and VICKS cough suppressant throat lozenges and medicated drops. Beyond its healthcare product offerings, this group manages ventures in real estate leasing, facility management, and hotel operations. Conversely, the Prescription Pharmaceutical Operation Group is dedicated to ethical drugs. Its portfolio includes Edirol, an active vitamin D3 agent for osteoporosis; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, another bisphosphonate medication for osteoporosis; Lusefi, a treatment for type 2 diabetes mellitus; and LOQOA, a transdermal anti-inflammatory analgesic. This division is actively engaged in developing new pharmaceuticals, particularly focusing on therapeutic areas such as central nervous system disorders, infectious diseases, metabolic conditions, and orthopedic complaints. Additionally, Taisho Pharmaceutical supplies essential raw materials for both pharmaceutical and quasi-drug production, and markets a range of health foods and skincare products. The company, which traces its origins back to 1912, is headquartered in Tokyo, Japan.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open TAIPY position with:
Real after-tax yield depends on where you live and how you hold TAIPY.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 1.23% | -1.57% | $123 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 1.05% | -1.75% | $105 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 0.98% | -1.82% | $98 / yr |
| 🇬🇧 UK ISA | 0% | 1.23% | -1.57% | $123 / yr |
| 🇬🇧 UK Taxable | 8.75% | 1.12% | -1.68% | $112 / yr |
| 🇨🇦 TFSA | 0% | 1.23% | -1.57% | $123 / yr |
| 🇨🇦 CA Taxable | 25% | 0.92% | -1.88% | $92 / yr |
| 🇦🇺 Super (pension) | 15% | 1.05% | -1.75% | $105 / yr |
| 🇦🇺 AU Taxable | 30% | 0.86% | -1.94% | $86 / yr |
| 🇩🇪 DE Taxable | 26.375% | 0.91% | -1.89% | $91 / yr |
| 🇫🇷 FR Taxable | 30% | 0.86% | -1.94% | $86 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $0.17/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
TAIPY pays quarterly — 4 times per year. Next ex-div: TBD.
How TAIPY compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for TAIPY sourced from FMP /financial-growth endpoint — real data, not estimates.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the TAIPY dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Taisho Pharmaceutical Holdings Co., Ltd. (TAIPY) is currently trading at $14.00, 19% below its 52-week high. The current dividend yield is 1.23% based on an annual payout of $0.17 per share.
Taisho Pharmaceutical Holdings Co., Ltd. (TAIPY) is a healthcare stock currently trading at $14.00 with a dividend yield of 1.23%. The company pays an annual dividend of $0.17 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings. Over the past 5 years, TAIPY has grown its dividend at a compound annual rate of 8.8%.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
⏱️ Takes 30 seconds · No signup · Free forever